EUVIMEDEUVIMED entdecken
Übersichtsarbeit

BRAF in non–small cell lung cancer: From molecular mechanisms to clinical practice

Claudia Parisi iD, David Planchard

Cancer · 15.03.2025 · 131 (S1)

DOI: 10.1002/cncr.35781 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 02.04.2025. Verfasst von Claudia Parisi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Cancer Group, Department of Medical Oncology, Gustave Roussy and International Center for Thoracic Cancers, Villejuif, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins B-raf, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

V‐Raf murine sarcoma viral oncogene homolog B ( BRAF ) mutations are found in up to 4% of patients with non–small cell lung cancer (NSCLC). Approximately 2% of advanced NSCLC cases harbor a BRAF V600E (class I) mutation. Because targeted therapies inhibiting BRAF (e.g., dabrafenib and encorafenib) and MEK (trametinib and binimetinib) are associated with improved outcomes as first‐ or second‐line treatment for BRAF V600E–mutant NSCLC, both European Society for Medical Oncology and National Comprehensive Cancer Network guidelines recommend testing for the BRAF V600E oncogenic driver at the time of diagnosis. In recent years, the treatment landscape of this molecular subgroup has seen great development. Different therapeutic strategies including anti–programmed death ligand 1 antibodies and kinase inhibitors have been assessed thus far, with novel agents (e.g., pan‐BRAF inhibitors) and therapeutic associations underway in preclinical and clinical trials. This review describes the current understanding of the BRAF clinicopathologic role in NSCLC, with a special focus on published trials assessing currently approved therapies. Mechanisms of drug resistance and future perspectives on the therapeutic approach of BRAF ‐deregulated NSCLC are also summarized.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins B-rafLung NeoplasmsHumansMutationProtein Kinase InhibitorsMolecular Targeted Therapy

Stichwörter der Autor:innen

BRAFBRAF V600E mutationBRAF inhibitorsclinical trialsinvestigational agentsliquid biopsynon–small cell lung cancer (NSCLC)resistance mechanisms

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Thoracic Cancer Group, Department of Medical Oncology, Gustave Roussy and International Center for Thoracic Cancers, Villejuif, France.
  • Paris-Saclay University, Villejuif, Kremlin-Bicêtre, France.
  • Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Rome, Italy.

ORCID-Profile: Claudia Parisi

Zitieren

APA

Parisi, C., & Planchard, D. (2025). BRAF in non–small cell lung cancer: From molecular mechanisms to clinical practice. Cancer, 131(S1). https://doi.org/10.1002/cncr.35781

Vancouver

Parisi C, Planchard D. BRAF in non–small cell lung cancer: From molecular mechanisms to clinical practice. Cancer. 2025;131(S1). doi:10.1002/cncr.35781

BibTeX
@article{Parisi2025,
  author = {Parisi, Claudia and Planchard, David},
  title = {BRAF in non–small cell lung cancer: From molecular mechanisms to clinical practice},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {S1},
  doi = {10.1002/cncr.35781}
}
Kostenlos starten →